Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Cell Prolif. 2012 Dec;45(6):557-65. doi: 10.1111/j.1365-2184.2012.00846.x. Epub 2012 Oct 10.
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) can affect post-translational processes, thus being responsible for decreased farnesylation and geranylgeranylation of intracellular small G proteins such as Ras, Rho and Rac, essential for cell survival and proliferation. In this regard, recent in vitro and in vivo studies suggest a possible role for both statins and farnesyl transferase inhibitors in the treatment of malignancies. Within such a context, the aim of our study was to investigate effects of either simvastatin (at concentrations of 1, 15, and 30 μm) or the farnesyl transferase inhibitor R115777 (at concentrations of 0.1, 1, and 10 μm), on two cultures of human non-small lung cancer cells, adenocarcinoma (GLC-82) and squamous (CALU-1) cell lines. In particular, we evaluated actions of these two drugs on phosphorylation of the ERK1/2 group of mitogen-activated protein kinases and on apoptosis, plus on cell numbers and morphology.
Western blotting was used to detect ERK phosphorylation, and to assess apoptosis by evaluating caspase-3 activation; apoptosis was also further assessed by terminal deoxynucleotidyl-mediated dUTP nick end labelling (TUNEL) assay. Cell counting was performed after trypan blue staining.
In both GLC-82 and CALU-1 cell lines, simvastatin and R115777 significantly reduced ERK phosphorylation; this effect, which reached the greatest intensity after 36 h treatment, was paralleled by a concomitant induction of apoptosis, documented by significant increase in both caspase-3 activation and TUNEL-positive cells, associated with a reduction in cell numbers. Our results thus suggest that simvastatin and R115777 may exert, in susceptible lung cancer cell phenotypes, a pro-apoptotic and anti-proliferative activity, which appears to be mediated by inhibition of the Ras/Raf/MEK/ERK signalling cascade.
3-羟基-3-甲基戊二酰辅酶 A(HMG-CoA)还原酶抑制剂(他汀类药物)可影响翻译后过程,从而负责细胞内小 G 蛋白如 Ras、Rho 和 Rac 的法呢基化和香叶基化,这些蛋白对细胞存活和增殖至关重要。在这方面,最近的体外和体内研究表明,他汀类药物和法尼基转移酶抑制剂都可能在恶性肿瘤的治疗中发挥作用。在这种情况下,我们的研究目的是研究辛伐他汀(浓度为 1、15 和 30μm)或法尼基转移酶抑制剂 R115777(浓度为 0.1、1 和 10μm)对两种人非小细胞肺癌细胞系腺癌(GLC-82)和鳞状细胞(CALU-1)的影响。特别地,我们评估了这两种药物对丝裂原活化蛋白激酶 ERK1/2 组磷酸化和细胞凋亡的作用,以及对细胞数量和形态的作用。
使用 Western 印迹检测 ERK 磷酸化,并通过评估半胱天冬酶-3 的激活来评估细胞凋亡;通过末端脱氧核苷酸转移酶介导的 dUTP 缺口末端标记(TUNEL)测定进一步评估细胞凋亡。通过台盼蓝染色后进行细胞计数。
在 GLC-82 和 CALU-1 细胞系中,辛伐他汀和 R115777 均显著降低 ERK 磷酸化;这种作用在 36 小时处理后达到最强强度,同时伴随着细胞凋亡的诱导,这通过半胱天冬酶-3 的激活和 TUNEL 阳性细胞的显著增加来证明,同时伴随着细胞数量的减少。我们的结果表明,辛伐他汀和 R115777 可能在易感肺癌细胞表型中发挥促凋亡和抗增殖作用,这似乎是通过抑制 Ras/Raf/MEK/ERK 信号级联来介导的。